Martin Pichler

Medical University of Graz
Country flagAustria

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

Articles (13)

Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) detect relapses earlier than conventional technology, and (iii) if elevated postoperative M371 levels may predict relapse. Experimental Design: In a multicentric setting, 258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques. Diagnostic characteristics of M371 for detecting relapses were calculated using ROC curve analysis. Results: Thirty-nine patients recurred (15.1%), all with elevated M371 levels; eight without relapse had elevations, too. The test revealed the following characteristics: area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%. Earlier relapse detection with the test was found in 28%, with non-significant median time gain to diagnosis. Postoperative M371 levels did not predict future relapse. Conclusions: The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for patients with testicular GCT.

Year:

2024

Purpose: Surveillance of clinical stage I (CSI) testicular germ cell tumors (GCT) is hampered by low sensitivity and specificity of current biomarkers for detecting relapses. This study evaluated if serum levels of microRNA371a-3p (M371 test) can: (i) Accurately detect relapses, (ii) detect relapses earlier than conventional technology, and (iii) if elevated postoperative M371 levels may predict relapse. Experimental Design: In a multicentric setting, 258 patients with testicular CSI GCT were prospectively followed by surveillance for a median time of 18 months with serial measurements of serum M371 levels, in addition to standard diagnostic techniques. Diagnostic characteristics of M371 for detecting relapses were calculated using ROC curve analysis. Results: Thirty-nine patients recurred (15.1%), all with elevated M371 levels; eight without relapse had elevations, too. The test revealed the following characteristics: area under the ROC curve of 0.993, sensitivity 100%, specificity 96.3%, positive predictive value 83%, negative predictive value 100%. Earlier relapse detection with the test was found in 28%, with non-significant median time gain to diagnosis. Postoperative M371 levels did not predict future relapse. Conclusions: The sensitivity and specificity of the M371 test for detecting relapses in CSI GCTs are much superior to those of conventional diagnostics. However, post-orchiectomy M371 levels are not predictive of relapse, and there is no significant earlier relapse detection with the test. In all, there is clear evidence for the utility of the M371 test for relapse detection suggesting it may soon be ready for implementation into routine follow-up schedules for patients with testicular GCT.

Year:

2024

Year:

2023

Year:

2023

Year:

2023

MicroRNAs (miRNAs) are crucial post-transcriptional regulators of gene expression, and their deregulation contributes to many aspects of cancer development and progression. Thus, miRNAs provide insight into oncogenic mechanisms and represent promising targets for new therapeutic approaches. A type of cancer that is still in urgent need of improved treatment options is triple negative breast cancer (TNBC). Therefore, we aimed to characterize a novel miRNA with a potential role in TNBC. Based on a previous study, we selected miR-4646-5p, a miRNA with a still unknown function in breast cancer. We discovered that higher expression of miR-4646-5p in TNBC patients is associated with better survival. In vitro assays showed that miR-4646-5p overexpression reduces growth, proliferation, and migration of TNBC cell lines, whereas inhibition had the opposite effect. Furthermore, we found that miR-4646-5p inhibits the tube formation ability of endothelial cells, which may indicate anti-angiogenic properties. By whole transcriptome analysis, we not only observed that miR-4646-5p downregulates many oncogenic factors, like tumor-promoting cytokines and migration- and invasion-related genes, but were also able to identify a direct target, the GRAM domain-containing protein 1B (GRAMD1B). GRAMD1B is involved in cellular cholesterol transport and its knockdown phenocopied the growth-reducing effects of miR-4646-5p. We thus conclude that GRAMD1B may partly contribute to the diverse tumor-suppressive effects of miR-4646-5p in TNBC.

Year:

2023

Year:

2023

Year:

2023

Year:

2022

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (25)

Julia Heinzelbecker

Clinic director

Philipps-Universität Marburg

GERMANY
View details

Josef Smolle

Professor

Medical University of Graz

AUSTRIA
View details

Erika Richtig

Prof

Medical University of Graz

AUSTRIA
View details

Ralf Küppers

Professor

Universität Duisburg-Essen

GERMANY
View details

Luis A. Kluth

-

GERMANY
View details

Laura Liesinger

TU Wien

AUSTRIA
View details

Akos Heinemann

Professor

Medical University of Graz

AUSTRIA
View details

Axel Heidenreich

-

GERMANY
View details

Peter Törzsök

Paracelsus Medical University

AUSTRIA
View details

Ruth Birner-Gruenberger

Full Professor

TU Wien

AUSTRIA
View details

Joerg Lindenmann

Medical University of Graz

AUSTRIA
View details

Gerald Hoefler

Professor for Pathology

Medical University of Graz

AUSTRIA
View details

Cátia Pacífico

-

AUSTRIA
View details

Klaus-Peter Dieckmann

Prof

Asklepios Klinik Altona

GERMANY
View details

Jürgen Eberle

Charité - Universitätsmedizin Berlin

GERMANY
View details

Freyja Maria Smolle-Juettner

Head of Division

Medical University of Graz

AUSTRIA
View details

Alan Ramsay

King’s College London

UNITED KINGDOM
View details

Frédéric Santer

Principal Investigator

Medical University of Innsbruck

AUSTRIA
View details

Jelena Krstic

Assistant Professor

Medical University of Graz

AUSTRIA
View details

Josef Fritz

Medical University of Innsbruck

AUSTRIA
View details

Alexander Winter

-

GERMANY
View details

Gennadi Tulchiner

Medical University of Innsbruck

AUSTRIA
View details

Renate Pichler

Medical University of Innsbruck

AUSTRIA
View details

Wilfried Renner

Medical University of Graz

AUSTRIA
View details

Beate Rinner

Head of Core Facility Alternative Biomodels and Preclinical Imaging

Medical University of Graz

AUSTRIA
View details